Assessing the proarrhythmic potential of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmias
- 22 May 2006
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 112 (1), 150-170
- https://doi.org/10.1016/j.pharmthera.2005.04.009
Abstract
No abstract availableKeywords
This publication has 250 references indexed in Scilit:
- Long‐term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine‐induced torsades de pointes arrhythmiasBritish Journal of Pharmacology, 2006
- Sex Modulates the Arrhythmogenic Substrate in Prepubertal Rabbit Hearts with Long QT 2Journal of Cardiovascular Electrophysiology, 2005
- Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3Cardiovascular Research, 2005
- Temporal repolarization lability differences among genotyped patients with the long QT syndromeThe American Journal of Cardiology, 2004
- Assessing predictors of drug-induced torsade de pointesTrends in Pharmacological Sciences, 2003
- Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointesBritish Journal of Pharmacology, 2002
- Spectrum of drugs prolonging QT interval and the incidence of torsades de pointesEuropean Heart Journal Supplements, 2001
- Mortality in the Survival With ORal D-Sotalol (SWORD) Trial: Why Did Patients Die?The American Journal of Cardiology, 1998
- Inherited ventricular arrhythmias and sudden death in German shepherd dogsJournal of the American College of Cardiology, 1994
- Female gender as a risk factor for torsades de pointes associated with cardiovascular drugsJama-Journal Of The American Medical Association, 1993